Business Wire

KONVI

27.6.2024 09:01:30 CEST | Business Wire | Press release

Share
Konvi Launches Once-in-a-Lifetime Alec Monopoly Birkin Bag Investment Opportunity

Konvi, Europe’s leading luxury assets fractional investment platform, has announced the launch of a once-in-a-lifetime opportunity to invest in an exclusive Birkin bag designed by Alec Monopoly. This is a particularly exciting investment as it combines a piece of art by a prestigious artist with one of the best investment vehicles in the world – the Birkin bag – and the firm expects a high degree of interest from investors.

The value of a Birkin bag increases immediately upon leaving the store, leading many to say it’s a better investment than gold. Having never fluctuated downwards in value, Birkins are highly lucrative investments that consistently outperform the S&P 500 and boast double-digit annual returns.

Alec Monopoly rose to fame through his bright-coloured graffiti art and paintings which explore the themes of capitalism and luxury lifestyles. Birkin bags designed by Monopoly retail between an astounding $11,900 and $300,000. The famous handbags have also been sported by celebrities, including Khloe Kardashian, who owns a $25,000 piece painted by the artist.

Luxury assets are much more than a popular accessory, as they provide strong investment opportunities. The fact that returns on luxury items are negatively correlated with those on equities, bonds, and other collectible investments, makes them a great addition to an investment portfolio to ensure strong diversification.

Through Konvi’s app, investors can buy fractional shares of the luxury Birkin bag starting from €250 with immediate effect. Konvi buys and insures the asset and then sells it at the highest price, returning money to the asset's co-owners. This model enables users to access an extremely rare investment that would usually require significant capital and a broad network of collectors and auction houses to invest in.

Eran Peer, Co-Founder and CEO, commented: “Launching this exclusive luxury Alec Monopoly Birkin bag investment opportunity for Konvi users is central to our goal of bringing previously inaccessible luxury investment opportunities to a broader range of people. This offering means people can own a share in a bag adorned by some of the biggest celebrities on the planet, including the Kardashians, and reap the investment rewards. We’re excited to be bringing such a high-performing asset to our platform and look forward to launching similar investment opportunities in the near future.”

Investing in luxury assets such as art, fine wines, whiskeys, watches and vintage cars has long been inaccessible to the majority of people. High up-front costs, low availability and opaque, private markets with high fees mean historically only the most sophisticated investors and wealthy individuals could capitalise on these opportunities.

Konvi is the first Pan-European investment platform that enables retail investors to diversify their portfolios by fractionally investing in luxury assets. By collaborating with industry experts with strong track records, Konvi ensures that investment opportunities on its platform are carefully curated and accessible to everyone. Konvi also recently launched its latest Banksy art investment with one of the leading Banksy art piece curators, TGB Contemporary.

Visit Konvi’s website to find out how you can invest in this Alec Monopoly Birkin bag: https://konvi.app/en_GB/

About Konvi

Konvi is a pioneering online platform that democratises access to alternative investments, including hand-curated art, fine wine, classic cars, and more. With a user-friendly interface and innovative strategies, Konvi empowers individuals to build diversified portfolios and achieve their financial goals starting from an investment of €250.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240627487145/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Fujirebio and Sysmex Begin Sales Collaboration for Dementia Testing5.2.2026 07:30:00 CET | Press release

Fujirebio Holdings, Inc. (HQ: Minato-ku, Tokyo; President & CEO: Goki Ishikawa; “Fujirebio”), a consolidated subsidiary of H.U. Group Holdings, Inc. (HQ: Minato-ku, Tokyo; Chairman, President and Group CEO: Shigekazu Takeuchi) and Sysmex Corporation (HQ: Kobe, Japan; President: Kaoru Asano, “Sysmex”) have agreed on a sales collaboration for dementia testing. This agreement follows continued discussions based on the Basic Agreement on Business Collaboration in the Field of Immunoassay concluded in October 2023.1 Sysmex will exclusively sell Fujirebio's fully automated Lumipulse® immunoassay systems and dementia-related reagents ("the Products") in regions and countries mutually agreed upon by both companies. Going forward, Fujirebio and Sysmex will collaborate to meet the growing testing needs accompanying the wider adoption of therapeutic drugs and will gradually expand the countries where the Products are sold. Since entering into the Basic Agreement on Business Collaboration in Octob

Invivoscribe® Launches LeukoStrat® KMT2A + MRD Assay to Advance High-Sensitivity Leukemia Testing in Clinical Trials and Patient Management Worldwide5.2.2026 06:30:00 CET | Press release

Invivoscribe, a leader in precision medicine and measurable residual disease (MRD) testing, today announced the addition of the LeukoStrat®KMT2A + MRD Assay and Software to its industry-leading oncology portfolio. The assay leverages digital PCR (dPCR) to support both screening and precise longitudinal MRD monitoring for KMT2A rearrangements in acute myeloid leukemia (AML) subjects. This quantitative test is currently available for research use in clinical trials and as a stand-alone kit for purchase by our global customers, and will soon be available as a service in our regional LabPMM® laboratories worldwide. The assay is available to detect key AML-associated KMT2A rearrangements, which account for the vast majority of KMT2A fusion partners in AML1 and those most commonly targeted in menin-inhibitor clinical development programs. Later this year, the assay will be enhanced with four additional KMT2A rearrangements which are frequently found in acute lymphocytic leukemia (ALL), expan

VeriSilicon Enhanced ISP8200-FS Series IP Achieves ASIL B Functional Safety Certification5.2.2026 01:00:00 CET | Press release

Enabling Next-Generation High-Performance Automotive Camera Systems VeriSilicon (688521.SH) today announced its latest enhanced versions of Image Signal Processing (ISP) IP ISP8200-FS series, ISP8200-ES and ISP8200L-ES, featuring improved performance and energy efficiency to better support complex automotive camera systems. These enhanced IPs have successfully achieved ISO 26262 ASIL B functional safety certifications issued by TÜV NORD, an international inspection and certification institution, further validating their suitability and reliability for ADAS and autonomous driving applications. The latest enhanced ISP8200-FS series IP can operate at up to 1.2 GHz and support data processing from up to 16 image sensors. It significantly improves the performance of multi-camera scheduling, enabling flexible data-access capabilities and efficient hardware pipeline utilization for automotive camera systems. The enhanced series IP integrates image processing technologies including Color Noise

Kinaxis Inc. to Host Fourth Quarter 2025 Financial Results Conference Call on March 5, 20264.2.2026 22:30:00 CET | Press release

Kinaxis® Inc. (TSX:KXS), a global leader in supply chain orchestration, today announced that it has scheduled its conference call to discuss the financial results for its fourth quarter and year ended December 31, 2025. The call will be hosted on Thursday, March 5 at 8:30 a.m. Eastern Time by Razat Gaurav, chief executive officer, and Blaine Fitzgerald, chief financial officer, followed by a question and answer period. The Company will report its financial results for the fourth quarter and year after the close of markets on Wednesday, March 4, 2026. CONFERENCE CALL DETAILS DATE: Thursday, March 5, 2026 TIME: 8:30 a.m. Eastern Time WEBCAST: https://events.q4inc.com/attendee/567578009 (available for three months) About Kinaxis Kinaxis is a leader in modern supply chain orchestration, powering complex global supply chains and supporting the people who manage them. Our powerful, AI-infused supply chain orchestration platform, Maestro, combines proprietary technologies and techniques that

Mainstay Medical Announces Exclusive Coverage of ReActiv8® by Blue Cross Blue Shield of North Dakota4.2.2026 22:30:00 CET | Press release

Mainstay Medical Holdings plc today announced that Blue Cross Blue Shield of North Dakota has established favorable coverage for the company’s ReActiv8 Restorative NeurostimulationTM therapy for the treatment of intractable chronic low back pain. The policy went into effect in January 2026 and specifies that ReActiv8 is the only therapy considered medically necessary by the policy when the conditions for coverage are met. “We are pleased that another Blue Cross Blue Shield payer has joined Anthem in making ReActiv8 available to well-selected patients after reviewing the large body of clinical evidence we have built,”said Jason Hannon, CEO of Mainstay Medical. “Patients with intractable chronic low back pain are desperately seeking durable solutions, and ReActiv8 has proven to be a safe and effective solution through six clinical studies with 633 patients treated and 1,950 patient-years of follow-up, including two multi-center, randomized controlled clinical studies. We look forward to

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye